Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: results from the ATAC trial

被引：0
|
作者：
Duffy, SR
Distler, W
机构：
[1] St James Univ Hosp, Leeds, W Yorkshire, England
[2] Univ Klinikum Carl Gustav Carus, Dresden, Germany
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S103 / S103
页数：1
相关论文
共 50 条
  • [41] Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
    Rosell, J.
    Nordenskjold, B.
    Bengtsson, N-O
    Fornander, T.
    Hatschek, T.
    Lindman, H.
    Malmstrom, P-O
    Wallgren, A.
    Stal, O.
    Carstensen, J.
    BRITISH JOURNAL OF CANCER, 2011, 104 (06) : 899 - 902
  • [42] The FACE trial: Letrozole or anastrozole as initial adjuvant therapy?
    Jonat, Walter
    Mundhenke, Christoph
    CANCER INVESTIGATION, 2007, 25 (01) : 14 - 18
  • [43] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial
    Boccardo, F
    Rubagotti, A
    Puntoni, M
    Guglielmini, P
    Amoroso, D
    Fini, A
    Paladini, G
    Mesiti, M
    Romeo, D
    Rinaldini, M
    Scali, S
    Porpiglia, M
    Benedetto, C
    Restuccia, N
    Buzzi, F
    Franchi, R
    Massidda, B
    Distante, V
    Amadori, D
    Sismondi, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5138 - 5147
  • [44] Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis
    Rocchi, A.
    Verma, S.
    SUPPORTIVE CARE IN CANCER, 2006, 14 (09) : 917 - 927
  • [45] Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
    J Rosell
    B Nordenskjöld
    N-O Bengtsson
    T Fornander
    T Hatschek
    H Lindman
    P-O Malmström
    A Wallgren
    O Stål
    J Carstensen
    British Journal of Cancer, 2011, 104 : 899 - 902
  • [46] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
    Howell, A
    Cuzick, J
    Baum, M
    Buzdar, A
    Dowsett, M
    Forbes, JF
    Hoctin-Boes, G
    Houghton, I
    Locker, GY
    Tobias, JS
    LANCET, 2005, 365 (9453) : 60 - 62
  • [47] Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole
    Carlson, RW
    Henderson, IC
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 80 : S19 - S26
  • [48] Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis
    A. Rocchi
    S. Verma
    Supportive Care in Cancer, 2006, 14 : 917 - 927
  • [49] Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)
    Eastell, Richard
    Hannon, Rosemary A.
    Cuzick, Jack
    Dowsett, Mitch
    Clack, Glen
    Adams, Judith E.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (08) : 1215 - 1223
  • [50] Tolerability of anastrozole (A) compared with tamoxifen (T): Mature data in the adjuvant setting - Data reported on behalf of the ATAC ('arimidex', tamoxifen, alone or in combination) trialists' group
    Mansel, Robert
    ANNALS OF ONCOLOGY, 2006, 17 : 94 - 94
12345